Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNext Regulatory News (NXT)

Share Price Information for Next (NXT)

Share Price is delayed by 15 minutes
Get Live Data
14,615.00    -100.00 (-0.68%)
Bid:
14,620.00
Ask:
14,630.00
Spread: 10.00 (0.068%)
Market Cap: £16.68b
NXT Live PriceLast checked at - London Stock Exchange

Intraday Next Share Chart

Director/PDMR Shareholding

3 Oct 2025 16:45

RNS Number : 0707C
Next PLC
03 October 2025
 

3 October 2025

NEXT plc

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them (PCA)

The following awards were granted to executive directors and a PCA on 3 October 2025 under the NEXT Long Term Incentive Plan (the "LTIP"):

Maximum No. of Shares

Lord Wolfson of Aspley Guise

8,776

Jonathan Blanchard

5,575

Richard Papp

6,504

Jane Shields

6,504

Jeremy Stakol

5,575

Marcelle Stakol (PCA)

1,014

Under the terms of each LTIP the award comprises a conditional award of shares on the following terms:

·

the award will vest following the third anniversary of the date of grant subject to performance targets and continued employment in the NEXT Group;

 

·

a variable percentage of the maximum number of shares above can vest, depending on the relative Total Shareholder Return of NEXT over a three year period against a comparator group;

 

·

for relative performance against the comparator group the percentage vesting will be:

 

Relative performance

Percentage vesting

Below median

0%

Median

20%

Upper quintile

100%

 

·

the Remuneration Committee has discretion to override and reduce formulaic outcomes under the LTIP awards should this be considered appropriate in the circumstances;

 

·

before any of the awards vest, the Committee must have regard to the underlying financial performance of the Company;

 

·

to the extent that the performance condition is not met, the award will lapse completely;

 

·

to the extent that awards vest, dividend equivalents will be accrued; and

 

·

any vesting of these awards granted (including dividend equivalents) will be settled in shares and, after payment of tax, the net shares received should be retained by executive directors for a period of two further years and PCAs for a further period of 6 months.

 

LTIP awards are made twice a year. The maximum number of shares shown above is 112.5% of each executive director's (60% of PCA's) base salary at the date of grant, divided by NEXT's average share price over the three months prior to the start of the performance period.

The following notification is made in accordance with article 19 of the UK Market Abuse Regulation ("MAR") and relates to awards granted to executive directors and a PCA on 3 October 2025 under the LTIP.

1

 

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

 

Name

 

1. Lord Wolfson of Aspley Guise

2. Jonathan Blanchard

3. Richard Papp

4. Jane Shields

5. Jeremy Stakol

6. Marcelle Stakol

 

2

Reason for the notification

a)

 

Position/status

 

1. Chief Executive (PDMR)

2. Chief Financial Officer (PDMR)

3. Group Merchandise and Operations Director (PDMR)

4. Group Sales, Marketing and HR Director (PDMR)

5. Group Investments, Acquisitions and Third Party Brands Director (PDMR)

6. Brand Director (PCA with Jeremy Stakol)

 

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

NEXT plc

b)

 

LEI

213800WQD8ECPZP9PH98

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.10 each - conditional award

Identification code

GB0032089863

b)

 

Nature of the transaction

 

 

 

 

 

 

 

 

Conditional award granted of shares under the LTIP. Maximum number of shares as follows:

1. Lord Wolfson of Aspley Guise - 8,776

2. Jonathan Blanchard - 5,575

3. Richard Papp - 6,504

4. Jane Shields - 6,504

5. Jeremy Stakol - 5,575

6. Marcelle Stakol - 1,014

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

Lord Wolfson of Aspley Guise

Nil

8,776

Jonathan Blanchard

Nil

5,575

Richard Papp

Nil

6,504

Jane Shields

Nil

6,504

Jeremy Stakol

Nil

5,575

Marcelle Stakol

Nil

1,014

d)

 

Aggregated information

- Aggregated volume

n/a single transactions

- Price

 

 

e)

 

Date of the transaction

 

3 October 2025

f)

 

Place of the transaction

 

Outside a trading venue

 

H Woodall-Pagan

Company Secretary

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFSEIELVIIE
Date   Source Headline
22nd Mar 20242:24 pmRNSDirector/PDMR Shareholding
22nd Mar 20249:15 amRNSDirector Declaration
21st Mar 20241:15 pmRNSDirector Declaration
21st Mar 202412:50 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSNEXT plc Results for the Year Ended January 2024
1st Mar 20249:00 amRNSTotal Voting Rights
19th Feb 20242:27 pmRNSClosed Period Share Repurchase Programme
15th Feb 20244:58 pmRNSTransaction in Own Shares
6th Feb 20245:12 pmRNSTransaction in Own Shares
2nd Feb 20245:10 pmRNSTransaction in Own Shares
1st Feb 20245:20 pmRNSTransaction in Own Shares
1st Feb 20248:00 amRNSTotal Voting Rights
23rd Jan 20245:17 pmRNSTransaction in Own Shares
23rd Jan 20242:44 pmRNSDirector Appointment
22nd Jan 20245:41 pmRNSTransaction in Own Shares
17th Jan 20243:48 pmRNSDirector/PDMR Shareholding - Replacement
17th Jan 202412:00 pmRNSDirector Appointment
5th Jan 202412:00 pmRNSDirector/PDMR Shareholding
5th Jan 202412:00 pmRNSDirector/PDMR Shareholding
4th Jan 20247:00 amRNSTrading Statement
2nd Jan 20248:00 amRNSTotal Voting Rights
19th Dec 20234:45 pmRNSHolding(s) in Company
4th Dec 202310:45 amRNSDirector/PDMR Shareholding
4th Dec 202310:34 amRNSDirector/PDMR Shareholding
1st Dec 20238:00 amRNSTotal Voting Rights
14th Nov 20234:57 pmRNSHolding(s) in Company
13th Nov 202312:30 pmRNSAGM Update
1st Nov 20238:00 amRNSTotal Voting Rights
1st Nov 20237:00 amRNSTrading Statement
19th Oct 20234:00 pmRNSDirector/PDMR Shareholding
18th Oct 20233:00 pmRNSNew Issue and Additional Listing
13th Oct 20233:11 pmRNSAcquisition of FatFace
3rd Oct 20233:19 pmRNSDirector/PDMR Shareholding
2nd Oct 20233:00 pmRNSBoard Changes
2nd Oct 20238:30 amRNSTotal Voting Rights
25th Sep 20235:15 pmRNSDirector/PDMR Shareholding
25th Sep 20235:09 pmRNSDirector/PDMR Shareholding
22nd Sep 20234:00 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSResults for the Half Year Ending July 2023
1st Sep 202312:00 pmRNSTotal Voting Rights
1st Sep 20239:30 amRNSAcquisition of Warburg Pincus’ Interest in Reiss
4th Aug 20234:07 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSTrading Statement
1st Aug 20238:34 amRNSTotal Voting Rights
12th Jul 20235:08 pmRNSTransaction in Own Shares
11th Jul 20235:46 pmRNSTransaction in Own Shares
10th Jul 20235:14 pmRNSTransaction in Own Shares
7th Jul 20235:10 pmRNSTransaction in Own Shares
6th Jul 20235:44 pmRNSTransaction in Own Shares
5th Jul 20235:43 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.